news
Steep drop for UK industry clinical trials between 2017 and 2021
COVID-19 has accelerated the decline in late-stage industry clinical research in the UK, compared to its global peers.
List view / Grid view
NHS
news
Political parties focus on R&D and mental health ahead of UK election
The three largest UK political parties have published their manifestos for the upcoming election which focus on various pharma initiatives including the NHS, R&D, drug prices and mental health.
news
NHS releases guidance to remove drugs from prescription list
Seven medications have been suggested for removal from prescriptions by the NHS after a public consultation.
news
Four drug companies accused of illegal market sharing
The CMA accuses four pharmaceutical firms of colluding to illegally inflate prices of an anti-nausea drug.
news
NHS announces groundbreaking personalised child cancer treatment
The NHS has announced a groundbreaking new treatment, CAR-T, for children with leukaemia...
news
UK-US post-Brexit trade deal risks increased drug prices
A trade deal between the UK and USA could risk increasing drug prices in the UK, which could diminish the affordability and accessibility of the NHS...
news
ABPI respond to statement of UK Government’s medicines regulation plans
The ABPI has responded to a joint letter from Jeremy Hunt, Secretary of State for Health, and Greg Clark, Secretary of State for Business, published by the Financial Times, that outlined the UK Government’s plans for the regulation of medicines as the UK leaves the European Union (EU).
news
Pfizer’s breast cancer drug too expensive for NHS
3 February 2017 | By Niamh Marriott, Digital Editor
NICE has today published draft guidance which does not recommend Pfizer's breast cancer drug palbociclib for routine funding on the NHS...
news
NICE approves former CDF kidney cancer drug for NHS use
12 January 2017 | By Niamh Marriott, Digital Editor
Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma...
news
NICE says Roche’s trastuzumab emtansine too expensive for routine NHS use
29 December 2016 | By Niamh Louise Marriott, Digital Editor
Trastuzumab emtansine is currently being funded through the Cancer Drugs Fund (CDF). NICE is looking again at its 2015 guidance to see whether it should...
news
NICE approves three quarters of CDF drugs for routine NHS use
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been reappraised by the National Institute for Health and Care Excellence (NICE) have received positive recommendations for routine use in the NHS. NICE has been reappraising cancer drugs which had not been recommended in previous NICE guidance…
news
Infirst’s treatment for chronic wounds now available on NHS
30 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Granulox increases levels of oxygen at the wound bed, speeding up the rate of healing in wounds, venous leg ulcers, by 75% compared to standard care...
news
NICE recommends Novartis’ ankylosing spondylitis drug
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...
news
NICE says Bayer’s liver cancer drug is not cost-effective
24 August 2016 | By The National Institute for Health and Care Excellence (NICE)
NICE originally published guidance in 2010 which said that sorafenib was not cost effective but it was then made available through the CDF. NICE is reconsidering sorafenib as part of its programme to appraise drugs that are currently available...
news
NICE says Novartis’ and Janssen’s cancer drugs are not cost effective
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective.
